Last reviewed · How we verify
montelukast in treatment of ENL reaction
montelukast in treatment of ENL reaction is a Small molecule drug developed by The Leprosy Mission Bangladesh. It is currently in Phase 1 development.
At a glance
| Generic name | montelukast in treatment of ENL reaction |
|---|---|
| Sponsor | The Leprosy Mission Bangladesh |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- montelukast in treatment of ENL reaction CI brief — competitive landscape report
- montelukast in treatment of ENL reaction updates RSS · CI watch RSS
- The Leprosy Mission Bangladesh portfolio CI
Frequently asked questions about montelukast in treatment of ENL reaction
What is montelukast in treatment of ENL reaction?
montelukast in treatment of ENL reaction is a Small molecule drug developed by The Leprosy Mission Bangladesh.
Who makes montelukast in treatment of ENL reaction?
montelukast in treatment of ENL reaction is developed by The Leprosy Mission Bangladesh (see full The Leprosy Mission Bangladesh pipeline at /company/the-leprosy-mission-bangladesh).
What development phase is montelukast in treatment of ENL reaction in?
montelukast in treatment of ENL reaction is in Phase 1.